Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBT (2016 - 2025)

Ani Pharmaceuticals' EBT history spans 15 years, with the latest figure at $31.5 million for Q4 2025.

  • For Q4 2025, EBT rose 328.74% year-over-year to $31.5 million; the TTM value through Dec 2025 reached $95.8 million, up 531.26%, while the annual FY2025 figure was $95.8 million, 531.26% up from the prior year.
  • EBT for Q4 2025 was $31.5 million at Ani Pharmaceuticals, down from $33.8 million in the prior quarter.
  • Across five years, EBT topped out at $33.8 million in Q3 2025 and bottomed at -$31.5 million in Q3 2024.
  • The 5-year median for EBT is -$1.1 million (2021), against an average of -$1.3 million.
  • The largest annual shift saw EBT plummeted 34057.89% in 2022 before it surged 1070.21% in 2024.
  • A 5-year view of EBT shows it stood at -$30.9 million in 2021, then surged by 81.57% to -$5.7 million in 2022, then soared by 116.65% to $947000.0 in 2023, then tumbled by 1553.22% to -$13.8 million in 2024, then soared by 328.74% to $31.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's EBT are $31.5 million (Q4 2025), $33.8 million (Q3 2025), and $10.5 million (Q2 2025).